The Multiple Myeloma (MM) market was impacted by newly diagnosed and relapsed / refractory data presented during the American Society of Hematology (ASH) meeting in Orlando, FL.

Breaking Data will worked with 30 oncologists during the meeting to better understand the commercial implications of data presented for: NINLARO® (ixazomib) + REVLIMID® (lenalidomide), DARZALEX® (daratumumab), CC-93269 (anti-BCMA), JNJ-4528/LCAR-B38M (anti-BCMA), bb21217 (anti-BCMA), VENCLEXTA® (venetoclax), KYPROLIS® (carfilzomib) + daratumumab.

Companies presenting data include: Takeda, Janssen, BMS, bluebird bio, Abbvie, Amgen.

Get immediate access to this 60-slide report so you can make better decisions today and prepare for tomorrow.

MULTIPLE MYELOMA Report ASH 2019

Orlando, FL
Dec 7 to Dec 11

Share: